专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016022016A3 CERVICOUTERINE DEVICE THAT INCREASES PROTECTION AGAINST THE RISK OF CONTRACTING CERVICOUTERINE CANCER 审中-公开
标题翻译：增加对合并癌症癌症风险的保护措施的CERVICETERINE DEVICE
公开(公告)号：WO2016022016A3
公开(公告)日：2017-03-23
申请号：PCT/MX2015000121
申请日：2015-08-27
申请人： SANDERS ACEDO GUILLERMO
发明人： SANDERS ACEDO GUILLERMO
IPC分类号： A61K33/34 , A61K9/00
CPC分类号： A61K9/0039 , A61K33/34 , A61K47/02 , A61K47/32 , A61K47/34 , A61K51/025
摘要： The present invention describes a cervicouterine device, in which the antiviral properties of copper have been directed, expanded and extended to reduce the risk of contracting cervicouterine cancer and to act as a prevention factor in cervical carcinogenesis. This is achieved by means of the concentration, increase and distribution of copper in the area of the female reproductive organs, comprising the lower part of the uterine cavity and also the endocervix, the incubation site for human papilloma virus, which is the main cause of cervicouterine cancer. The cervicouterine device as disclosed increases the ionic capacity of the copper by increasing the surface area thereof to 418 mm2, and the turns of the coil are separated from one another, incorporating an extension made from the same material, and same being positioned directly in the cervix, said extension having the form of a coil, a Solomon Bar, bracelet or Celtic knot, the copper filaments being assembled on a plastic framework of different dimensions that correspond to the proportions of the uterine cavity, in accordance with the parity thereof.
摘要翻译：本发明描述了一种宫颈癌装置，其中铜的抗病毒性质被引导，扩展和扩展，以降低颈部癌细胞癌的收缩风险，并且作为宫颈癌发生的预防因素。这是通过在女性生殖器官区域中的铜的浓度，增加和分布来实现的，其包括子宫腔的下部以及人乳头状瘤病毒的孵育位点的内切宫颈，这是人类乳头状瘤病毒的主要原因宫颈癌所公开的颈椎器装置通过将其表面积增加到418mm 2而增加了铜的离子容量，并且线圈的匝彼此分离，并且包括由相同材料制成的延伸部分，并且其直接位于子宫颈，所述延伸部具有线圈形式，所罗门杆，手镯或凯尔特结，铜丝根据其奇偶性被组装在对应于子宫腔的比例的不同尺寸的塑料框架上。

2. 发明申请

WO2015017378A2 NOVEL COPPER-CYSTEAMINE AND METHODS OF USE 审中-公开
标题翻译：新型铜蛋白和使用方法
公开(公告)号：WO2015017378A2
公开(公告)日：2015-02-05
申请号：PCT/US2014048557
申请日：2014-07-29
申请人： UNIV TEXAS
发明人： CHEN WEI , MA LUN
IPC分类号： A61K31/30 , A61K49/00
CPC分类号： A61K41/0057 , A61K31/30 , A61K51/025 , A61K51/0478 , A61N5/062 , A61N5/10 , A61N2005/0661 , A61N2005/1087 , A61N2005/1089 , A61N2005/109 , C07F1/08 , C12N13/00 , G21K4/00 , A61K2300/00
摘要： Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a = 7.5510(4) Å, b = 16.9848(7) Å, c = 7.8364(4) Å, &bgr; = 104.798(3)°. The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.
摘要翻译：提供了一种新的Cu-Cyteamine（Cu-Cy）晶体材料的结构和发光特性。 Cu-Cy的晶体结构由单晶X射线衍射确定。发现该化合物在单斜空间群C2 / c中结晶，并且细胞参数为a = 7.5510（4），b = 16.9848（7），c = 7.8364（4），bgr; = 104.798（3）°。本发明的新型Cu-Cy晶体材料也可用于治疗癌症。

3. 发明申请

WO2012031118A3 CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX 审中-公开
标题翻译： ANAPHASE促进络合物的细胞可渗透抑制剂
公开(公告)号：WO2012031118A3
公开(公告)日：2012-07-19
申请号：PCT/US2011050203
申请日：2011-09-01
申请人： HARVARD COLLEGE , KING RANDALL , ZENG XING
发明人： KING RANDALL , ZENG XING
IPC分类号： A61K31/155 , A61K31/198 , A61K31/337 , A61K31/63 , A61P35/00
CPC分类号： A61K31/325 , A61K31/155 , A61K31/198 , A61K31/337 , A61K31/63 , A61K45/06 , A61K51/025
摘要： The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents.
摘要翻译：本发明提供了用于治疗细胞周期紊乱的组合物和方法。本发明的组合物包括proTAME，TAME的前药类似物，以及任选的一种或多种治疗剂。

4. 发明申请

WO2010117992A3 COUPLED IDENTIFICATION AND TREATMENT OF CANCER 审中-公开
标题翻译：联合检测和治疗癌症
公开(公告)号：WO2010117992A3
公开(公告)日：2011-02-24
申请号：PCT/US2010030054
申请日：2010-04-06
申请人： BERNSTEIN LAWRENCE
发明人： BERNSTEIN LAWRENCE
IPC分类号： A61K33/24 , A61K33/00 , A61P35/00
CPC分类号： A61K51/0402 , A61K31/28 , A61K31/7135 , A61K33/24 , A61K45/06 , A61K51/02 , A61K51/025 , A61K51/0472 , A61K2300/00
摘要： Provided are methods to treat cancer in which a patient is identified as having gallium-avid cancer by use of a gallium scan or other means, and is then treated with a pharmaceutically acceptable gallium composition.
摘要翻译：提供了治疗癌症的方法，其中通过使用镓扫描或其他方法将患者鉴定为具有镓 - 癌症，然后用药学上可接受的镓组合物治疗。

5. 发明申请

WO2004022105A3 PREPARATION OF M(CO)3-COMPLEXES BY SOLID PHASE TECHNIQUES VIA METAL ASSISTED CLEAVAGE FROM THE SOLID SUPPORT 审中-公开
标题翻译：通过固体相位技术制备M（CO）3复合物，通过金属辅助固体固体支架清除
公开(公告)号：WO2004022105A3
公开(公告)日：2004-04-22
申请号：PCT/US0327665
申请日：2003-09-02
申请人： MALLINCKRODT INC , ALBERTO ROGER , MUNDWILER STEFAN
发明人： ALBERTO ROGER , MUNDWILER STEFAN
IPC分类号： A61K47/48 , A61K51/04 , A61K51/12 , C07F1/08 , C07F13/00 , C07F15/00
CPC分类号： A61K51/025 , C07B2200/11 , C07F13/005
摘要： The present invention relates to a process for generating a water soluble metal complexed agent, comprising contacting a solid phase bound organic conjugate represented by the formula I with [M(H2O)3(CO)3] , under suitable conditions to cause the formation of a coordinate bond between [M(H2O)3(CO)3] and the tertiary amine nitrogen atom of the solid phase bound organic conjugate and thereby the release of the metal complexed agent thus formed from the support. The invention further relates to the conjugate of formula (I) and to a kit for performing the process.
摘要翻译：本发明涉及一种产生水溶性金属络合剂的方法，包括在合适的条件下使在合适条件下使式I的固相结合的有机共轭与[M（H 2 O）3（CO）3] n + 在[M（H 2 O）3（CO）3] n +>和固相结合的有机共轭物的叔胺氮原子之间形成配位键，由此由载体形成的金属络合剂的释放。本发明还涉及式（I）的缀合物和用于进行该方法的试剂盒。

6. 发明申请

WO1983003761A1 ISONITRILE RADIONUCLIDE COMPLEXES FOR LABELLING AND IMAGING AGENTS 审中-公开
标题翻译：用于标记和成像试剂的异烟碱放射性核素复合物
公开(公告)号：WO1983003761A1
公开(公告)日：1983-11-10
申请号：PCT/US1983000638
申请日：1983-04-26
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , MASSACHUSETTS INSTITUTE OF TECHNOLOGY
发明人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , JONES, Alun, G. , DAVISON, Alan , ABRAMS, Michael, J.
IPC分类号： A61K43/00
CPC分类号： A61K51/1234 , A61K51/025 , A61K2123/00 , C07C251/00 , C07F13/005
摘要： A coordination complex of an isonitrile ligand and radionuclide such as Tc, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb and Ta, is useful as a diagnostic agent for labelling liposomes or vesicles, and selected living cells containing lipid membranes, such as blood clots, myocardial tissue, gall bladder tissue, etc.

7. 发明申请

WO2017005648A1 RADIOTHERAPEUTIC PARTICLES AND SUSPENSIONS 审中-公开
标题翻译：放射治疗颗粒和悬浮液
公开(公告)号：WO2017005648A1
公开(公告)日：2017-01-12
申请号：PCT/EP2016/065573
申请日：2016-07-01
申请人： ONCOINVENT AS
发明人： WESTRØM, Sara , LARSEN, Roy, Hartvig
IPC分类号： A61K51/02 , A61K51/10 , A61K51/12 , A61P35/00 , A61K103/00
CPC分类号： A61K51/025 , A61K51/02 , A61K51/103 , A61K51/1093 , A61K51/1244 , C01F11/18 , C01P2004/64 , C01P2006/44
摘要： The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. A particle comprising CaCO 3 , the alpha emitting radionuclide 224 Ra, and a 224 Ra radionuclide progeny is in particular disclosed. The particles are beneficial for use in the treatment of cancer.
摘要翻译：本发明涉及一种颗粒或药物组合物，其包含一种，更多颗粒或包含可降解化合物和α发射放射性核素和/或产生α发射子的放射性核素的相同或不同颗粒的颗粒或悬浮液。特别公开了包含CaCO 3，α发射放射性核素224Ra和224Ra放射性核素后代的颗粒。该颗粒有益于用于治疗癌症。

8. 发明申请

WO2016018896A1 METAL(LOID) CHALCOGEN NANOPARTICLES AS UNIVERSAL BINDERS FOR MEDICAL ISOTOPES 审中-公开
标题翻译：金属（LOID）CHALCOGEN NANOPARTICLES作为医学同位素的通用粘合剂
公开(公告)号：WO2016018896A1
公开(公告)日：2016-02-04
申请号：PCT/US2015/042441
申请日：2015-07-28
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： WALL, Matthew A. , SHAFFER, Travis , HARMSEN, Stefan , GRIMM, Jan , KIRCHER, Moritz F.
IPC分类号： A61K51/12
CPC分类号： A61K51/1244 , A61K51/025 , A61K51/1251 , B82Y15/00
摘要： The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.
摘要翻译：本公开尤其提供了用于制备用于医学成像和/或治疗应用的医用同位素标记金属（loid）硫属元素纳米颗粒的新技术。所提供的技术与以前可用于制备和利用医学同位素的选择相比具有许多优点，例如，它们使用用作通用粘合剂的金属（卤素）硫族元素纳米颗粒（例如，通过共价或非共价键（例如，螯合）键），用于医学同位素，以提供医学同位素标记的金属（loid）硫属元素纳米颗粒。令人惊奇的是，相同的金属（卤素）硫族元素纳米颗粒可用于结合（例如共价或非共价例如螯合）键合）各种不同有用的医学同位素，而不使用传统的螯合剂。

9. 发明申请

WO2012143713A3 RADIOACTIVE SOLUTIONS FOR TREATING CANCER 审中-公开
标题翻译：用于治疗癌症的放射性解决方案
公开(公告)号：WO2012143713A3
公开(公告)日：2013-02-07
申请号：PCT/GB2012050852
申请日：2012-04-18
申请人： DSPI LTD , KNOX PETER
发明人： KNOX PETER
IPC分类号： A61K51/12 , A61P35/00
CPC分类号： A61K51/02 , A61K51/025 , A61K51/121
摘要： The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion.
摘要翻译：本发明提供了一种治疗肿瘤或其它病变的方法，包括将包含一种或多种放射性同位素的溶液直接引入哺乳动物的所述肿瘤或其他损伤中，以使肿瘤或其它病变中的放射性沉淀物原位沉淀。

10. 发明申请

WO2011049405A3 OPTICAL IMAGING CONTRAST AGENT, USE AND DEVICE THEREOF 审中-公开
标题翻译：光学成像造影剂，用途和装置
公开(公告)号：WO2011049405A3
公开(公告)日：2011-09-29
申请号：PCT/KR2010007287
申请日：2010-10-22
申请人： KYUNGPOOK NAT UNIV IND ACAD , YOO JEONG-SOO , PARK JEONG CHAN
发明人： YOO JEONG-SOO , PARK JEONG CHAN
IPC分类号： A61K51/00 , A61K101/00 , A61K103/30 , A61P35/00
CPC分类号： G01T1/164 , A61K49/0002 , A61K49/0067 , A61K49/1857 , A61K51/02 , A61K51/025 , A61K51/0491 , A61K51/1051 , A61K51/1244 , G01T7/08
摘要： The present invention relates to an optical imaging contrast agent, the use and a device thereof. The optical imaging contrast agent of the present invention does not need to comprise a separate fluorescent material or luminescent material to emit light, and can thus acquire an optical image without changing the physicochemical properties of an original molecule. The optical imaging contrast agent of the present invention can be used as an optical/nuclear medical dual imaging contrast agent in many cases, and enables the effects of treatment to be monitored from optical images concurrently with radiotherapy. In addition, when linked with a fluorescent material, the optical imaging contrast agent of the present invention can emit light from the fluorescent material with energy independently generated from the optical contrast agent without being supplied with energy from outside, and thus allows the amount of light to be increased and the tissue permeability to be enhanced.
摘要翻译：本发明涉及一种光学成像造影剂，其用途和装置。本发明的光学成像造影剂不需要包括单独的荧光材料或发光材料来发光，并且因此可以获得光学图像而不改变原始分子的物理化学性质。本发明的光学成像造影剂在很多情况下可以用作光学/核医学双成像造影剂，并且能够在放疗的同时从光学图像监测治疗效果。另外，本发明的光学成像造影剂在与荧光材料连接时，不用从外部供给能量就能够利用光造影剂独立产生的能量从荧光材料发射光，从而允许光量增加，组织渗透性增强。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式